Spanish Lung Cancer Group — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Spanish Lung Cancer Group appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials26

Recruiting shown1

Roles2

SourceClinicalTrials.gov

Clinical trials

26 shown

LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)NCT04344002 · lead sponsor · 2020-04-21

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCNCT03526887 · lead sponsor · 2018-07-15

Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain MetastasisNCT03526900 · lead sponsor · 2018-07-07

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionSNCT03496766 · lead sponsor · 2018-05-07

T790M Mutation Testing in Blood by Different MethodologiesNCT03363139 · lead sponsor · 2018-03-01

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish PatientNCT03132493 · lead sponsor · 2017-06-01

Durvalumab in HIV-1 Patients With Solid TumorsNCT03094286 · lead sponsor · 2017-04-24

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsNCT03081689 · lead sponsor · 2017-04-15

Pembrolizumab in Elderly Patients With Advanced Lung CancerNCT03293680 · lead sponsor · 2017-01-15

Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung CarcinomaNCT03156868 · lead sponsor · 2016-08-03

Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLCNCT02709720 · lead sponsor · 2016-04-15

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneNCT01513174 · lead sponsor · 2011-08-01

Observational Post-authorization Studies Carboplatin, Paclitaxel and BevacizumabNCT01814163 · lead sponsor · 2011-02-01

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLCNCT01088906 · lead sponsor · 2010-01-01

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.NCT00503971 · lead sponsor · 2008-05-01

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung CarcinomaNCT00617656 · lead sponsor · 2008-02-01

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)NCT00478699 · lead sponsor · 2007-06-01

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFRNCT00446225 · lead sponsor · 2007-02-15

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced AdenocarcinomaNCT00883480 · lead sponsor · 2005-06-01

Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung CancerNCT01652820 · lead sponsor · 2001-10-01

Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung CancerNCT00913705 · lead sponsor · 1999-09-01

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized TrialNCT07015892 · collaborator · 2026-03-01

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung CancerNCT02183870 · collaborator · 2014-05-01

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)NCT01562028 · collaborator · 2012-06-01

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung CancerNCT00433563 · collaborator · 2008-04-01

Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCGNCT00037713 · collaborator · 1998-09-01

Drugs studied in this sponsor's trials

14 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Spanish Lung Cancer Group as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

docetaxel4

cisplatin3

erlotinib3

gemcitabine2

pembrolizumab2

atezolizumab1

bevacizumab1

carboplatin1

docetaxel RxCUI 72962 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials erlotinib RxCUI 337525 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials gemcitabine RxCUI 12574 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial crizotinib RxCUI 1148495 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gefitinib RxCUI 328134 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nivolumab 10 MG/ML RxCUI 1597877 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial vinorelbine RxCUI 39541 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor21

collaborator5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.